Boston Scientific Corp. vs. LENSAR, Inc. Common Stock
Boston Scientific Corp. (BSX) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| BSX | LNSR | |
|---|---|---|
| Market Cap | $71.55 billion | $103.69 million |
| Revenue (TTM) | $21.00 billion | $60.26 million |
| Net Income (TTM) | $3.67 billion | $34.70 million |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | LNSR | |
|---|---|---|
| P/E Ratio | 20.39 | — |
| Price / Book | 2.84 | 6.96 |
| Price / Sales | 3.41 | 1.72 |
BSX and LNSR split the valuation factors evenly.
Profitability
| BSX | LNSR | |
|---|---|---|
| Net Margin | 17.47% | 57.57% |
| Return on Equity | 14.58% | 232.78% |
LNSR leads on 2 of 2 profitability factors.
Risk & Sentiment
| BSX | LNSR | |
|---|---|---|
| Short Interest | 0.72% | 5.49% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, LNSR overview, LNSR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.